Biopharmaceutical company Annexon (ANNX) is showing promising results in developing treatments for inflammatory-related diseases. Its flagship candidate, ANX005, showed positive topline Phase 3 data ...

KYOTO, Japan — Eculizumab (Soliris, Alexion Pharmaceuticals) is safe for the treatment of patients with severe Guillain-Barré syndrome (GBS), a new phase 2 study shows. However, although more patients ...

Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (ANNX) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...

Guillain-Barré Syndrome (GBS) is a rare but serious autoimmune disorder in which the immune system mistakenly attacks the peripheral nerves. Much like an electrical wire is insulated, nerves in the ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...

By Nevedita Singh: Maharashtra, India, has recently reported a concerning rise in GBS syndrome cases, particularly in regions like Pune. According to health officials, this surge has been linked to a ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that attack ...

The city witnessed the first death caused by Guillain-Barré Syndrome (GBS) this year on Monday night, as a 53-year-old man died during treatment at civic-run B L Nair Hospital in Mumbai Central. Amid ...